Two weeks after the CDL treatment, more than 90% of CD11b+/CD68+ TAM were depleted in the tumor region of the OUBC, whereas the CL treatment did not affect the number of CD11b+/CD68+ TAM in the tumor (Additional File 3). The gene discussed is SGMS2; the disease is neoplasm.